Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation.

Department of Surgery, Centre for Cancer Research, Queen Mary Hospital, University of Hong Kong Medical Centre, Pokfulam, Hong Kong, China.
Liver international: official journal of the International Association for the Study of the Liver (Impact Factor: 4.41). 06/2008; 28(5):622-31. DOI: 10.1111/j.1478-3231.2008.01687.x
Source: PubMed

ABSTRACT Hepatic resection is not applicable to a certain proportion of hepatocellular carcinoma patients owing to an insufficient liver function reserve. The present study was designed to investigate the effects of cardiotrophin-1 (CT-1) on improving the function of CCl(4)-induced cirrhotic liver remnant after major hepatectomy.
CT-1 was administered to rats after hepatectomy according to different protocols.
A double-dose CT-1 protocol improved liver function, enlarged the volume of liver remnant, upregulated the expression of von Willebrand factor and increased the number of BrdU(+) or Ki-67(+) hepatocytes. Administration of CT-1 enhanced the expression of nuclear factor-kappaB (P65), vascular endothelial growth factor (VEGF), CyclinD1 and p42/44 in the liver remnant. However, the effects of CT-1 were blocked by a VEGF receptor blocker, PTK787. Although the expression of gp130, a receptor of CT-1, was downregulated in the diseased hepatocytes isolated from the cirrhotic liver, CT-1 could still stimulate the cell proliferation. CT-1 administration enhanced the expression of P65 and VEGF in the diseased hepatocytes, but the augmented P65 and VEGF expression was blocked by PTK787 administration.
Short-term administration of CT-1 could improve the function of cirrhotic liver remnant and stimulate liver regeneration through promotion of angiogenesis and cell proliferation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Although generally reversible, contrast media toxicity often induces contrast-induced nephropathy (CIN), which is associated to longer hospitalization time, the need of dialysis, and higher incidence of later cardiovascular events and higher mortality. Preventive co-treatments have been assayed at the preclinical and clinical levels, but recent meta-analysis have not demonstrated a beneficial effect, which supports the search for new nephroprotective strategies. We have assessed if the administration of cardiotrophin-1 (CT-1), an endogenous cytokine with protective properties on the heart and liver, might mitigate CIN in rats. We have developed a model of CIN induced by the administration of the contrast medium gastrographin i.v. (3.7 mg/kg). in rats sensitized by previous administration of sub-nephrotoxic doses of gentamicin (50 mg/kg/day, i.p.) for 6 days. The severity of CIN was assessed by measurement of renal function, renal histological damage, urinary excretion of markers of tubular damage including NAG, KIM-1 and PAI-1, lipid peroxidation and renal apoptosis. Treatment with cardiotrophin-1 almost completely prevented the renal tissue damage as evidenced by almost total prevention of tubular desepithelization and tubular obstruction, reduced caspase activation and cell proliferation. Besides, CT-1 also prevented the increment in renal tissue levels of renal tissue injury markers NAG, KIM-1 and NGAL. Oxidative stress, a hallmark of contrast-induced nephropathy, was also prevented by CT-1. Administration of CT-1 also prevented the derangement in kidney function induced by CIN. Renal hemodynamics, also impaired by the contrast medium, were normal in rats co-treated with CT-1. Cardiotrophin-1 administration significantly prevents the alterations in renal function and structure observed in a rat model of CIN.
    Toxicological Sciences 01/2013; · 4.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Liver cancer typically occurs with a background of chronic fibrosis, characterized by the accumulation of myofibroblast-like cells. We performed 2D-PAGE based comparative analyses with the aim to identify proteins expressed in human hepatocellular carcinoma (HCC) tissue but not in neighboring healthy liver tissue, and to make out which cell types are responsible for the expression of proteins most characteristic for HCC. LC-MS/MS analysis of the most striking spots identified proteins which were mainly related to myofibroblast-like cells. To gain more insights into the role of these cells in their contribution to HCC, we isolated myofibroblast-like cells as well as hepatocytes, both derived from HCC tissues, and subjected them to proteome profiling based on shotgun experiments. Comparative analysis, also referring to proteome profiles of other cell types previously investigated by us, pointed again to a marked contribution of myofibroblast-like cells to HCC. Intriguingly, secretome analysis of these cells identified several growth factors which may act as tumor promoters and several proteins which have been described as potential biomarkers for HCC including dickkopf-1, connective tissue growth factor and CXCL1. Other biomarker candidates presently identified in the secretome of myofibroblasts, including lipocalin-1and pappalysin-1, may be selected for future clinical validation. The identification of myofibroblast-like cells as important source of tumor-promoters may open new avenues to therapeutic intervention by targeting these stroma cells in addition to the cancer cells. This article is protected by copyright. All rights reserved.
    Electrophoresis 10/2013; 34(24). · 3.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Organ fibrosis and architectural remodeling can severely disrupt tissue function, often with fatal consequences. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli, and the key cellular mediator of fibrosis comprises the myofibroblasts which, when activated, serve as the primary collagen-producing cells. Complex links exist between fibrosis, regeneration and carcinogenesis, and the concept that all organs contain common tissue fibrosis pathways that could be potential therapeutic targets is an attractive one. Because of the major impact of fibrosis on human health there is an unmet need for safe and effective therapies that directly target fibrosis. Halofuginone inhibits tissue fibrosis and regeneration, and thereby affects the development of tumors in various tissues along the gastrointestinal tract. The high efficacy of halofuginone in reducing the fibrosis that affects tumor growth and tissue regeneration is probably due to its dual role in inhibiting the signaling pathway of transforming growth factor β, on the one hand, and inhibiting the development of Th17 cells, on the other hand. At present halofuginone is being evaluated in a clinical trial for other fibrotic indication, and any clinical success in that trial would allow the use of halofuginone, also for all other fibrotic indications, including those of the gastrointestinal tract.
    World Journal of Gastroenterology 10/2014; 20(40):14778-14786. · 2.43 Impact Factor


1 Download
Available from